Constituents from Entada scandens with TRAIL-resistance Overcoming Activity

Firoj Ahmed; Kazufumi Toume; Naoki Ishikawa; Midori A. Arai; Samir K. Sadhu; Masami Ishibashi

doi:10.1177/1934578x1601100731

Constituents from Entada scandens with TRAIL-resistance Overcoming Activity

Firoj Ahmed, Kazufumi Toume, Naoki Ishikawa, Midori A. Arai, Samir K. Sadhu, Masami Ishibashi

Research output: Contribution to journal › Article › peer-review

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has emerged as a promising anticancer agent because of its ability to selectively kill tumor cells. But TRAIL-resistance is a major problem of its therapy. A search for compounds for abrogating TRAIL-resistance has, thus, become an important strategy for anticancer drug discovery. In search of bioactive natural products for overcoming TRAIL-resistance, we previously reported some compounds with TRAIL-resistance overcoming activity. Bioassay guided fractionation of Entada scandens led to the isolation of four compounds (1-4). Of the isolates, compounds 1 and 3 showed moderate TRAIL-resistance overcoming activity in TRAIL-resistant human gastric adenocarcinoma (AGS) cells.

Original language	English
Pages (from-to)	993-995
Number of pages	3
Journal	Natural product communications
Volume	11
Issue number	7
DOIs	https://doi.org/10.1177/1934578x1601100731
Publication status	Published - 2016 Jul
Externally published	Yes

Keywords

Entada scandens
TRAIL-resistance overcoming activity

ASJC Scopus subject areas

Pharmacology
Plant Science
Drug Discovery
Complementary and alternative medicine

Access to Document

10.1177/1934578x1601100731

Cite this

@article{fe25686f1fbc495397b22424b41c2597,

title = "Constituents from Entada scandens with TRAIL-resistance Overcoming Activity",

abstract = "Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has emerged as a promising anticancer agent because of its ability to selectively kill tumor cells. But TRAIL-resistance is a major problem of its therapy. A search for compounds for abrogating TRAIL-resistance has, thus, become an important strategy for anticancer drug discovery. In search of bioactive natural products for overcoming TRAIL-resistance, we previously reported some compounds with TRAIL-resistance overcoming activity. Bioassay guided fractionation of Entada scandens led to the isolation of four compounds (1-4). Of the isolates, compounds 1 and 3 showed moderate TRAIL-resistance overcoming activity in TRAIL-resistant human gastric adenocarcinoma (AGS) cells.",

keywords = "Entada scandens, TRAIL-resistance overcoming activity",

author = "Firoj Ahmed and Kazufumi Toume and Naoki Ishikawa and Arai, {Midori A.} and Sadhu, {Samir K.} and Masami Ishibashi",

year = "2016",

month = jul,

doi = "10.1177/1934578x1601100731",

language = "English",

volume = "11",

pages = "993--995",

journal = "Natural Product Communications",

issn = "1934-578X",

publisher = "Natural Product Communications",

number = "7",

}

TY - JOUR

T1 - Constituents from Entada scandens with TRAIL-resistance Overcoming Activity

AU - Ahmed, Firoj

AU - Toume, Kazufumi

AU - Ishikawa, Naoki

AU - Arai, Midori A.

AU - Sadhu, Samir K.

AU - Ishibashi, Masami

PY - 2016/7

Y1 - 2016/7

N2 - Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has emerged as a promising anticancer agent because of its ability to selectively kill tumor cells. But TRAIL-resistance is a major problem of its therapy. A search for compounds for abrogating TRAIL-resistance has, thus, become an important strategy for anticancer drug discovery. In search of bioactive natural products for overcoming TRAIL-resistance, we previously reported some compounds with TRAIL-resistance overcoming activity. Bioassay guided fractionation of Entada scandens led to the isolation of four compounds (1-4). Of the isolates, compounds 1 and 3 showed moderate TRAIL-resistance overcoming activity in TRAIL-resistant human gastric adenocarcinoma (AGS) cells.

AB - Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has emerged as a promising anticancer agent because of its ability to selectively kill tumor cells. But TRAIL-resistance is a major problem of its therapy. A search for compounds for abrogating TRAIL-resistance has, thus, become an important strategy for anticancer drug discovery. In search of bioactive natural products for overcoming TRAIL-resistance, we previously reported some compounds with TRAIL-resistance overcoming activity. Bioassay guided fractionation of Entada scandens led to the isolation of four compounds (1-4). Of the isolates, compounds 1 and 3 showed moderate TRAIL-resistance overcoming activity in TRAIL-resistant human gastric adenocarcinoma (AGS) cells.

KW - Entada scandens

KW - TRAIL-resistance overcoming activity

UR - http://www.scopus.com/inward/record.url?scp=85019056173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019056173&partnerID=8YFLogxK

U2 - 10.1177/1934578x1601100731

DO - 10.1177/1934578x1601100731

M3 - Article

AN - SCOPUS:85019056173

SN - 1934-578X

VL - 11

SP - 993

EP - 995

JO - Natural Product Communications

JF - Natural Product Communications

IS - 7

ER -

Constituents from Entada scandens with TRAIL-resistance Overcoming Activity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this